Catherine E Storrer
Overview
Explore the profile of Catherine E Storrer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amin A, Benavides L, Holmes J, Gates J, Carmichael M, Hueman M, et al.
Cancer Immunol Immunother
. 2008 Apr;
57(12):1817-25.
PMID: 18392824
Background: E75, a HER2/neu immunogenic peptide, is expressed in breast cancer (BCa). We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at...
2.
Peoples G, Holmes J, Hueman M, Mittendorf E, Amin A, Khoo S, et al.
Clin Cancer Res
. 2008 Feb;
14(3):797-803.
PMID: 18245541
Purpose: E75 is an immunogenic peptide from the HER2/neu protein, which is overexpressed in many breast cancer patients. We have conducted two overlapping E75 vaccine trials to prevent recurrence in...
3.
Dehqanzada Z, Storrer C, Hueman M, Foley R, Harris K, Jama Y, et al.
Oncol Rep
. 2007 Feb;
17(3):687-94.
PMID: 17273752
We used the Luminex assay to compare serum cytokine profiles of breast cancer patients (BCa) to healthy controls, node-positive (NP) patients to node-negative (NN), and pre- and post-vaccination serum of...
4.
Mittendorf E, Storrer C, Shriver C, Ponniah S, Peoples G
Ann Surg Oncol
. 2006 Jul;
13(8):1085-98.
PMID: 16865596
Background: Trastuzumab, an anti-HER2/neu monoclonal antibody, is thought to promote HER2/neu receptor internalization and/or turnover. This study was designed to investigate the kinetics of trastuzumab treatment on tumor cells with...
5.
Hueman M, Stojadinovic A, Storrer C, Dehqanzada Z, Gurney J, Shriver C, et al.
Cancer Immunol Immunother
. 2006 Jun;
56(2):135-46.
PMID: 16783576
We are conducting clinical trials of the E75 peptide as a vaccine in breast cancer (BrCa) patients. We assessed T cell subpopulations in BrCa patients before and after E75 vaccination...
6.
Hueman M, Stojadinovic A, Storrer C, Foley R, Gurney J, Shriver C, et al.
Breast Cancer Res Treat
. 2006 Jun;
98(1):17-29.
PMID: 16758122
Purpose: We are conducting clinical trials in breast cancer (BrCa) patients to test the HER2/neu peptide vaccine (E75). We have investigated the impact of this vaccine on circulating levels of...
7.
Mittendorf E, Storrer C, Foley R, Harris K, Jama Y, Shriver C, et al.
Cancer
. 2006 Apr;
106(11):2309-17.
PMID: 16596621
Background: E75 and GP2 are human leukocyte antigen (HLA)-A2-restricted immunogenic peptides derived from the HER2/neu protein. In a E75 peptide-based vaccine trial, preexisting immunity and epitope spreading to GP2 was...
8.
Mittendorf E, Gurney J, Storrer C, Shriver C, Ponniah S, Peoples G
Surgery
. 2006 Mar;
139(3):407-18.
PMID: 16546506
Background: We are conducting clinical vaccine trials with the HER2/neu peptide, E75, in patients with breast cancer. The purpose of this study was to demonstrate clonal expansion of E75-specific CD8(+)...
9.
Dehqanzada Z, Storrer C, Hueman M, Foley R, Harris K, Jama Y, et al.
Clin Cancer Res
. 2006 Jan;
12(2):478-86.
PMID: 16428490
Purpose: We studied serum monocyte chemotactic protein-1 (MCP-1) levels in breast cancer patients in relationship to their clinicopathologic variables and immune response to a /neu E75 vaccine. Experimental Design: We...
10.
Hueman M, Dehqanzada Z, Novak T, Gurney J, Woll M, Ryan G, et al.
Clin Cancer Res
. 2005 Oct;
11(20):7470-9.
PMID: 16243821
Purpose: The E75 peptide is an immunogenic peptide from the HER-2/neu protein that is substantially expressed in prostate cancer. We are conducting a clinical trial of an E75/granulocyte macrophage colony-stimulating...